Pilots are often the first real validation moment for Health Tech founders. They prove your solution works in practice, open doors with NHS trusts and private providers, and build the case study bank you need for investor conversations.

But pilots don’t pay salaries, and they don’t satisfy investors indefinitely. Too many Health Tech startups accumulate pilot wins without ever converting them into contracts – what investors have started calling the “pilot trap.” If you want to scale, you need a deliberate strategy for moving from trial to revenue.

Why NHS Pilots Rarely Convert on Their Own

The NHS is not a single buyer. Since the transition from Clinical Commissioning Groups to Integrated Care Boards (ICBs), commissioning decisions have become more complex – budgets sit across multiple organisations, and procurement processes vary significantly between trusts.

Even when clinical stakeholders are enthusiastic about a pilot, conversion barriers are substantial. Budget cycles rarely align with pilot timelines, meaning a successful result in Q2 may not translate into a procurement decision until the following financial year. Moving from pilot to rollout often requires a fresh procurement process, sometimes via NHS frameworks such as Crown Commercial Service or NHS Shared Business Services. And before any NHS trust can move to wider deployment, Digital Technology Assessment Criteria (DTAC) compliance – covering clinical safety, data protection, and technical interoperability – typically needs to be evidenced formally.

Understanding these barriers upfront, rather than assuming conversion will follow naturally from clinical success, is what separates founders who escape the pilot trap from those who don’t.

Set Conversion Terms Before the Pilot Starts

The most effective way to avoid the pilot trap is to treat every pilot as a sales process in progress from the first conversation.

Before a pilot begins, agree in writing what success looks like and what the pathway to a contract will be if those criteria are met. Set a defined timeline – open-ended pilots tend to drift. Identify internal champions who have both the willingness and the authority to advocate for adoption at budget and procurement level. If DTAC compliance is a requirement for full deployment, scope out what evidence needs to be collected during the pilot to satisfy it, rather than treating compliance as a separate post-pilot task.

This shifts the relationship from “let’s try this” to “let’s test this before we roll it out” – a small framing change that makes a material difference to how conversion conversations develop.

Prove Clinical and Commercial Impact

Clinical validation is necessary but not sufficient. NHS decision-makers operate under significant financial pressure, and procurement teams and ICB finance leads will scrutinise the economic case alongside the clinical one.

Quantify cost savings in terms buyers care about – staff time released, bed days avoided, readmissions reduced, or diagnostic speed improved. Frame outcomes using the NICE Evidence Standards Framework for digital health technologies where possible – it provides a recognised structure that commissioners use to assess whether an innovation is ready for adoption. A clear budget impact model showing what your solution costs versus what it saves at trust or ICB level is increasingly expected before a procurement decision can move forward. Investors want to see the same thing: economic evidence, not just clinical results.

Get Pricing Right Before Scale

One of the more common reasons pilots stall commercially is that pricing hasn’t been worked through at rollout scale. Pilots delivered for free or at cost create a gap between the trial experience and the commercial conversation that’s harder to bridge than most founders expect.

Test pricing assumptions during the pilot where possible. Even a nominal contribution from the trust signals that this is a commercial relationship rather than a research project. Develop tiered models showing how pricing works at different adoption levels – per-patient, per-clinic, or per-licence structures are generally easier for NHS finance teams to model and budget for. For early-stage Health Tech companies, SBRI Healthcare – the NHS’s Small Business Research Initiative – offers funded problem-solving contracts that provide non-dilutive revenue while building the evidence base needed for wider adoption. It’s an underused route that’s worth understanding before you decide whether your pilot should be free.

Build Revenue Streams Beyond the NHS

NHS conversion timelines are long, and a business model that depends on a single system moving at NHS pace is a risk investors will push back on – particularly when you’re trying to demonstrate traction between rounds.

Parallel revenue streams to pursue alongside NHS pilots include private healthcare providers (faster procurement cycles and direct commercial incentives), corporate occupational health and employee wellbeing programmes, and international markets where adoption dynamics may be more favourable. Academic Health Science Networks (AHSNs) are also worth engaging – they act as intermediaries between innovators and trusts across their region and can accelerate NHS adoption for founders who’ve already demonstrated clinical results at one site. Showing investors that your revenue model works beyond a single NHS contract is one of the most effective ways to de-risk the fundraising conversation.

Keep Investors Confident Through the Long Cycle

Investors who back Health Tech understand that NHS adoption takes time. What concerns them is the absence of a credible plan for what happens while it does. Model your pilot-to-contract conversion rates – even conservatively – and show how different adoption scenarios affect your runway and revenue projections. Best, base, and downside cases in your forecast tell investors you’ve stress-tested the assumptions rather than assumed the best case.

Non-dilutive funding from Innovate UK or NHS England innovation programmes can help extend runway during slow adoption cycles without further diluting the cap table – worth building into your funding strategy alongside equity rounds.

The startups that escape the pilot trap are the ones that plan for conversion before the pilot starts, build commercial evidence alongside clinical evidence, and show investors a credible, costed path to scale.